Economic evaluation of point-of-care testing and treatment for sexually transmitted and genital infections in pregnancy in low- and middle-income countries: A systematic review

Olga P. M. Saweri1,2*, Neha Batura3, Rabiah Al Adawiyah1, Louise M. Causer1, William S. Pomat2, Andrew J. Vallely1,2, Virginia Wiseman1,4

1 The Kirby Institute, University of New South Wales, Sydney, Australia, 2 The Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea, 3 University College London, London, United Kingdom, 4 London School of Hygiene and Tropical Medicine, London, United Kingdom

* nsawe ri@kirby.unsw.edu.au

Abstract

Background
Sexually transmitted and genital infections in pregnancy are associated with adverse pregnancy and birth outcomes. Point-of-care tests for these infections facilitate testing and treatment in a single antenatal clinic visit and may reduce the risk of adverse outcomes. Successful implementation and scale-up depends on understanding comparative effectiveness of such programmes and their comparative costs and cost effectiveness. This systematic review synthesises and appraises evidence from economic evaluations of point-of-care testing and treatment for sexually transmitted and genital infections among pregnant women in low- and middle-income countries.

Methods
Medline, Embase and Web of Science databases were comprehensively searched using pre-determined criteria. Additional literature was identified by searching Google Scholar and the bibliographies of all included studies. Economic evaluations were eligible if they were set in low- and middle-income countries and assessed antenatal point-of-care testing and treatment for syphilis, chlamydia, gonorrhoea, trichomoniasis, and/or bacterial vaginosis. Studies were analysed using narrative synthesis. Methodological and reporting standards were assessed using two published checklists.

Results
Sixteen economic evaluations were included in this review; ten based in Africa, three in Latin and South America and three were cross-continent comparisons. Fifteen studies assessed point-of-care testing and treatment for syphilis, while one evaluated chlamydia. Key drivers of cost and cost-effectiveness included disease prevalence; test, treatment, and staff costs; test sensitivity and specificity; and screening and treatment coverage. All studies...
Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: WANTAIM is a partnership of academic and governmental institutions in Papua New Guinea, Australia and Europe. The trial is funded by a Joint Global Health Trials award from the UK Department for International Development, the UK Medical Research Council and the Wellcome Trust (MR/N006089/1); a Project Grant from the Australian National Health and Medical Research Council (GNT1084429); and a Research for Development award from the Swiss National Science Foundation (IZ07Z0_160909/1). OPMS within the manuscript and its Supporting Information files.

Competing interests: The authors have no competing interests.

Abbreviations: BV, bacterial vaginosis; CHEERS, consolidated health economic evaluation reporting standard; CT, chlamydia; DALYs, disability-adjusted-life-years; dRDT, dual rapid diagnostic test for HIV and syphilis; dRST, dual rapid syphilis test to determine Treponema and non-Treponema infections; HIV, human immunodeficiency virus; hRDT, point-of-care test for HIV; IEC, Information/ Education/Communication; LMIC, low- and middle-income countries; MDA, mass drug administration; NG, gonorrhoea (NG), chlamydia (CT), trichomiasis (TV) and bacterial vaginosis (BV); PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RPR, repaid plasma regain test; RST, rapid syphilis test; STI, sexually transmitted and genital infections; TPHA test, Treponema pallidum haemagglutination assay test; TV, Trichomiasis.

Introduction

Sexually transmitted and genital infections (henceforth, referred to as STIs) during pregnancy are associated with a number of adverse pregnancy and birth outcomes [1–9] and their burden is highest in low- and middle-income countries (LMICs) [10–12]. Among the most prevalent infections are the curable STIs: syphilis, gonorrhoea (NG), chlamydia (CT), trichomiasis (TV) and bacterial vaginosis (BV) [13, 14]. Untreated STIs in pregnancy can be associated with miscarriage, pre-term birth, stillbirth, low birth weight and neonatal eye and respiratory infections [15, 16].

Evidence shows that early detection and treatment of HIV and syphilis during pregnancy reduces the risk of adverse pregnancy and birth outcomes [17–20]. The World Health Organization (WHO) currently recommends HIV and syphilis testing for all pregnant women attending antenatal clinics [21–23]. The recommendation is driven by the commitment to eliminate the mother-to-child-transmission of HIV and syphilis [24]. Effective screening programs in antenatal clinics therefore play a pertinent role in ensuring early detection and treatment of HIV and syphilis, which directly improve maternal and child health.

Interventions utilised for diagnosing and/or treating STIs are illustrated in Table 1. For more than two decades, the diagnosis of STIs in many LMIC settings has been based on the WHO-endorsed strategy of syndromic management i.e. clinical diagnosis with no laboratory confirmation [25]. Syndromic management is often inaccurate and misses asymptomatic infections that make up a significant proportion of STIs in women [26, 27]. Laboratory-based

| Intervention                  | Definition                                                                 |
|-------------------------------|-----------------------------------------------------------------------------|
| Syndromic management          | Identification of signs and symptoms associated with STIs and commencing treatment to alleviate symptoms and treat the infection [32]. |
| Laboratory-based testing      | Diagnosing STIs by determining the etiological agents responsible for the current infection. Testing requires skilled personnel and controlled conditions specific to a laboratory setting. Results may not be available to the clinician until several days later, requiring patients to return for the results and treatment at a later date [33]. |
| Point-of-care testing         | Diagnosing STIs by determining the etiological agent responsible for the current infection at the time of the initial patient consultation. Specimen transport is minimised or not required. Minimal training is required to perform the test. Testing may be done onsite in front of or near to the patient. Patients should ideally receive results and treatment prior to leaving the clinic [34]. |

https://doi.org/10.1371/journal.pone.0253135.t001
diagnosis is beyond the reach of many health services in LMICs due to technical requirements and costs and even where it is available, delays in testing and the provision of results often prevent the timely initiation of treatment [28–31].

Technological advancements and the drive to find diagnostic solutions suitable for use at point-of-care have led to the development of a number of accurate, portable, simple-to-use and low-cost tests that are reshaping the global landscape of STI diagnosis and management [35]. These include rapid, point-of-care tests for HIV and syphilis that have been adopted and scaled up in many antenatal clinic settings and more recently, molecular assays for the diagnosis of CT, NG, and TV [36–38]. These new tests hold considerable promise for LMICs [39–41].

As with any health technology, it is crucial to consider any clinical benefits of point-of-care testing and treatment for STIs in pregnancy along with the associated costs of implementation and scale-up. This is especially important for LMICs that need to prioritise investment across a range of diagnostic technologies, treatments, and diseases within a relatively small fiscal space [42]. For these countries, there is considerable interest in weighing up the potential savings associated with the rapid delivery of results, reduced loss-to-follow-up and reduction of facility costs versus the long-run benefits associated with a laboratory confirmed diagnosis [43]. A new landscape for diagnostics is emerging in LMICs [37, 41, 44] and understanding the resource implications [45] and equity impact [46–48] on the health system and patients is a priority for policymakers [49]. To date, there have been no systematic reviews of the economic evidence relating to point-of-care testing and treatment for STIs in pregnancy. Consolidation and appraisal of studies in this field is timely and necessary for formulating strategies to achieve Sustainable Development Goal (SDG) 3: ensuring good health and well-being [50]. SDG 3 includes ending preventable deaths of newborns and children under 5 years of age and ensuring universal access to sexual and reproductive healthcare services [50, 51]. This systematic review examines economic evaluations of point-of-care testing and treatment of the most burdensome, curable STIs in pregnancy in LMICs. The specific objectives of this review are to:

1. Identify and synthesise the evidence from economic evaluations of point-of-care testing and treatment for STIs in pregnancy in LMICs;
2. Compare and contrast the findings, including key drivers of costs and cost-effectiveness; and
3. Appraise methodological and reporting quality using the Drummond 10 point checklist [52] and the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) checklist [53].

**Materials and methods**

The methods for this review follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (S1 File). The methodology summarised below adheres to the published systematic review protocol [54]. The review is registered in PROSPERO (CRD42018109072).

**Literature search and study selection**

A comprehensive literature search was conducted by two researchers (OPMS and NB) in MEDLINE, Embase, and Web of Science and completed in April 2020. The search terms, shown in Table 2, were developed with the help of medical librarians to ensure a sensitive search specific to the objectives of the systematic review. All database searches were identical. Keywords and MeSH terms framed the searches, while truncation was used to capture multiple
terms and the Boolean operators “OR” and “AND” to combine sub-heading search terms. Thereafter, a simplified version of the search was conducted in Google Scholar and restricted to the first 100 citations. Finally, a hand search of the bibliographies of the articles selected for full text review was conducted.

Two researchers independently conducted the database searches, screened records, titles and abstracts using Microsoft Excel (version 365), read full texts, and hand searched references of the included articles (OPMS and NB). The full texts were independently assessed against the eligibility criteria. A third senior researcher resolved any disagreements (VW).

Studies were included in this review if they:

• conducted a full economic evaluation (comparing the costs and consequences of two or more options and include cost effectiveness analyses (CEAs), cost utility analyses (CUAs), cost-benefit analyses, or cost consequence analyses [55]) or a partial economic evaluation (measuring program or disease costs without comparisons with alternative options or outcomes [55]) of a point-of-care testing and treatment intervention for syphilis, NG, CT, TV or BV;

• focused on pregnant women;

• took place in at least one LMIC, as defined by the World Bank [56]; and

• were full papers published in a peer-reviewed journal (commentaries, conference abstracts, editorials, protocols, and review papers were excluded).

No publication date nor language filter was applied.

### Data extraction and analysis

Data were extracted into a form developed, using Microsoft Excel (version 365), specifically for this review. Variables extracted were guided by the categories in the CHEERS checklist and included: study setting; type of STI; type of economic evaluation; time horizon; type of testing and treatment intervention and comparator; study perspective; types of costs; measures of effectiveness and cost-effectiveness; and sensitivity analysis results.

Data extraction highlighted the significant methodological heterogeneity between studies in terms of interventions, study design, cost categories, and health outcomes. Consequently,
neither a meta-analysis nor a sub-group meta-analysis was able to be performed as originally envisaged [54]. The analysis for this review was limited to a descriptive summary and narrative synthesis. This entailed the tabulation of study characteristics and a comprehensive assessment of relevant themes [57]. In addition, percentage differences were calculated to demonstrate a unitless relative difference and describe how cost-effective an intervention is. The percentage difference is calculated by finding the absolute difference in cost-effectiveness ratios dividing them by the average of the two values and multiplying this by 100. Percentage differences alongside cost-effectiveness decision rules and key outcomes emphasize between study heterogeneity. No additional statistical analyses were performed.

Study appraisal
Two checklists were used to appraise the methodological quality and reporting standards of the studies included in this review. Methodological quality was assessed using the 10 point, 13-criteria Drummond checklist [52] and reporting quality was appraised using the CHEERS checklist [53]. Together the checklists ensure reporting transparency and consistency of appraisal of the studies included in this systematic review and optimised their comparability across common themes. Each item on the checklist was assigned ‘Yes’, ‘No’ or ‘Unclear’ and where the checklist item was not applicable, ‘N/A’, was used. All studies included in this systematic review were independently appraised by two researchers (OPMS and NB). A third, senior, researcher (VW) resolved any disagreements.

Results
Search results
A total of 532 studies were identified after the initial search of the electronic databases. Sixteen studies fulfilled the inclusion criteria. The selection strategy is illustrated by the PRISMA flow diagram in Fig 1.

Tables 3 and 4 summarise the key results of this systematic review. All studies assessed antenatal point-of-care testing and treatment for syphilis [58–70], except for one that focused on CT [71]. Two studies that assessed syphilis also evaluated point-of-care testing and treatment for HIV in pregnant women [72, 73]. Most studies were conducted in Africa (n = 10) [58, 59, 61–64, 66, 70, 71, 73], while three were conducted in Latin and South America [67, 68, 72] and the remaining three involved cross-country comparisons [60, 65, 69]. Of the single country analyses, four countries were classified as low-income countries [63, 68, 70, 73] and seven as middle-income countries [59, 62, 64, 66, 67, 71, 72]. For the remaining multi-country studies, the majority of countries were middle-income countries [58, 60, 61, 65, 69].

Economic evaluations

Type of economic evaluation. Economic evaluations were categorised as either partial or full evaluations Table 3 indicates that four studies were partial economic evaluations [60, 63, 64, 72]. The remaining 12 studies were full economic evaluations, which included two cost-consequence analyses [61, 73] and 10 CEAs [58, 59, 62, 65–71], seven of which were CUAs [58, 65–70].

Perspectives, costs, and outcomes. Nine studies conducted an economic evaluation using trial data [59, 60, 63, 64, 66–69, 72], while seven studies utilised existing literature [58, 61, 62, 65, 70, 71, 73]. Ten studies took a provider perspective [58–60, 63–66, 69, 71, 72], three took a societal perspective [61, 68, 73] and three studies did not specify the perspective taken [62, 67, 70]. The most common types of costs measured were direct and indirect medical costs.
related to tests and/or treatment, staff time, and other consumables such as medical supplies. Patient costs were rarely captured (n = 4) due to a provider perspective being taken by most studies.

All studies in this review compared a point-of-care testing and treatment intervention against one or more comparators as shown by Fig 2. Four studies compared laboratory-based testing with a point-of-care testing and treatment strategy [60, 63, 67, 70]. Six studies compared point-of-care testing and treatment against multiple comparators including laboratory testing, another point-of-care test, mass drug administration (MDA), syndromic management and/or no screening program [59, 61, 62, 68, 69, 73].

Most cost-effectiveness studies found point-of-care testing and treatment more cost-effective compared to laboratory-based testing [62, 67, 68, 70], no screening [58, 65, 66] or syndromic management [71] as shown in Table 4. For the full economic evaluations (n = 12), a variety of effects were measured. Most studies measured effectiveness by estimating the number of cases of adverse outcomes averted, such as miscarriage, stillbirth, neonatal death and congenital syphilis [58, 61, 65–71, 73].
Table 3. Summary characteristics of economic evaluations for point-of-care tests for STIs in pregnancy in LMIC.

| Author and Reference number | Study setting   | Infection studied | Perspective | Comparators | Time Horizon        | Cost components                          | Health outcomes                                      | Efficiency measures                               |
|-----------------------------|-----------------|-------------------|--------------|-------------|---------------------|------------------------------------------|------------------------------------------------------|---------------------------------------------------|
|                             | Partial Economic Evaluations                                      |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |
| Shelley et al (2015) [64]   | Zambia           | Syphilis          | Provider     | Rapid Syphilis Test (RST) rollout vs. RST pilot | One year or less | 1. Test 2. Staff 3. Treatment 4. Supplies/ Consumables 5. Transport 6. Supervision 7. Quality Assurance and Control | Not applicable                                      | Average cost per woman screened                  |
| Sweeney et al (2014) [63]   | Tanzania         | Syphilis          | Provider     | RST vs. Rapid Plasma Reagin (RPR)               | One year or less | 1. Test 2. Staff 3. Treatment 4. Supplies/ Consumables 5. Training 6. Information Education Communication (IEC) material | Not applicable                                      | Average cost per woman screened                  |
| Obure et al (2017) [72]     | Colombia         | Syphilis and HIV  | Provider     | Dual HIV and Syphilis point-of-care test (dRDT) vs. HIV point-of-care test (hRDT) and RST | One year or less | 1. Test 2. Staff 3. Treatment 4. Supplies/ Consumables 5. Training 6. IEC material 7. Lab 8. Guidelines 9. Promotion | Not applicable                                      | Average cost per woman screened                  |
| Levin et al (2007) [60]     | Bolivia & Mozambique | Syphilis        | Provider     | RST vs. RPR                                    | Not reported     | 1. Test 2. Staff 3. Treatment 4. Supplies/ Consumables 5. Training 6. IEC material 7. Lab 8. Guidelines 9. Promotion | Not applicable                                      | Average cost per woman screened                  |
|                             | Full Economic Evaluations                                          |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |
| Bristow et al (2016) [73]   | Malawi           | Syphilis          | Societal     | dRDT vs. 1. hRDT 2. hRDT and RST 3. hRDT and TPHA | Lifetime         | 1. Test 2. Staff 3. Treatment 4. Patient out-of-pocket (OOP) expenses 5. Cost of delivery and immediate post-natal costs | Adverse pregnancy outcomes                           | Total cost & DALYs averted                       |
| Owusu-Edusei et al (2011) [61] | Sub-Saharan Africa | Syphilis         | Societal and Provider | Dual RST (dRST) vs. 1. RST 2. Onsite RPR 3. Lab based RPR and TPHA 4. No screening | Lifetime         | 1. Test 2. Staff 3. Treatment 4. Patient OOP expenses 5. Cost of delivery and immediate post-natal costs | Adverse pregnancy outcomes                           | Total cost & DALYs averted                       |

(Continued)
| Author and Reference number | Study setting | Infection studied | Perspective | Comparators | Time Horizon | Cost components | Health outcomes | Efficiency measures |
|-----------------------------|---------------|------------------|-------------|-------------|--------------|----------------|-----------------|-------------------|
| Kuznik et al (2015) [65]    | Latin America and Asia | Syphilis | Provider | RST vs. No screening | Not reported | 1. Test 2. Staff 3. Treatment | 1. Neonatal death 2. Still birth 3. Congenital syphilis | incremental cost/DALY averted |
| Terris-presthol et al (2015) [69] | Peru, Tanzania and Zambia | Syphilis | Provider | 1. RPR 2. RST 3. dRST (and treat all positives) 4. dRST (only treat if nTrp is positive) 5. RST followed by RPR 6. RPR followed by RST 7. RST followed by dRST (and treat all positives) 8. RST followed by dRST (only treat if nTrp is positive) 9. MDA vs. No screening | Not reported | 1. Test 2. Staff 3. Treatment 4. Supplies/Consumables 5. Fixed clinic costs 6. RPR equipment 7. System costs | 1. Neonatal death 2. Still birth 3. Congenital syphilis | cost/DALY averted |
| Kuznik et al (2013) [58]    | Sub-Saharan Africa | Syphilis | Provider | RST vs. No screening | Not reported | 1. Test 2. Staff 3. Treatment | 1. Neonatal death 2. Still birth 3. Congenital syphilis | average cost/DALY averted |
| Rydzak and Goldie (2008) [62] | South Africa | Syphilis | Not reported | 1. RST 2. RPR confirmed with TPHA vs. No screening | Lifetime | 1. Test 2. Staff 3. Treatment 4. Supplies/Consumables 5. Patient OOP expenses 6. Cost of delivery and immediate post-natal costs | 1. Neonatal death 2. Still birth 3. Congenital syphilis 4. Low birthweight (LBW) 5. Miscarriage | discounted costs saved per 1000 women |
| Schackman et al (2007) [68] | Haiti | Syphilis | Societal (CEA) and Provider (Scale up) | RST vs. 1. Syndromic management (in rural setting) 2. RPR (in urban setting) | Not reported | 1. Test 2. Staff 3. Treatment 4. Patient OOP expenses | 1. Neonatal death 2. Still birth 3. Congenital syphilis | Total incremental cost/DALY averted |
| Vickerman et al (2006) [70] | Tanzania | Syphilis | Not reported | RST (4 types of tests) vs. RPR | Not reported | 1. Test 2. Staff 3. Treatment | Adverse birth outcomes | total cost/DALY saved |
| Blandford et al (2007) [59] | South Africa | Syphilis | Provider | 1. Off-site RPR then TPHA; 2. Onsite RPR 3. RST vs. No screening | One year or less | 1. Test 2. Staff 3. Treatment 4. Supplies/Consumables | Congenital syphilis | total incremental cost/cases averted |
| Mallma et al (2016) [67]   | Peru | Syphilis | Not reported | RST vs. RPR | Not reported | 1. Test 2. Staff 3. Treatment 4. Supplies/Consumables | Adverse birth outcomes | cost/DALY averted |

(Continued)
Three-quarters of the full economic evaluations (n = 9) calculated incremental cost effectiveness ratios (ICERs), typically defined as the incremental cost per disability adjusted life years (DALY) averted or the incremental cost per case averted/cured [35, 37–40, 42, 43, 45, 46]. The ICERs reported varied considerably due to the heterogeneity of methods used to derive cost-effectiveness; therefore, making comparability difficult. The percentage differences emphasise the heterogeneity between studies included in this review. The greatest percentage difference between comparators was 170.6% (Cost/DALY of 63.1 and 5), while the smallest was 19.2% (Cost/DALY of 17 and 11.8).

Key drivers of economic evaluations
A sensitivity analysis was performed in 14 studies (87.5%) by varying key assumptions and recording the impact this had on the findings of the evaluation. Ten studies conducted a

Table 3. (Continued)

| Author and Reference number | Study setting | Infection studied | Perspective | Comparators | Time Horizon | Cost components | Health outcomes | Efficiency measures |
|-----------------------------|---------------|-------------------|-------------|-------------|--------------|----------------|-----------------|-------------------|
| Romoren et al (2007) [74]   | Botswana      | Chlamydia         | Provider    | 1. syndromic management with Azithromycin treatment; 2. point-of-care testing with Erythromycin treatment; 3. point-of-care testing with Azithromycin treatment vs. Syndromic management with Erythromycin treatment | One year or less | Point-of-care testing and treatment: 1. Test 2. Staff 3. Treatment Syndromic management: 1. Staff 2. Treatment 3. Training 4. Supervision | 1. Neonatal death 2. Still birth 3. Congenital syphilis | incremental cost/cases cured |
| Larson et al (2014) [66]    | Zambia        | Syphilis          | Provider    | No screening program vs. 1. 62% of antenatal care attendees tested, only 10% of positive cases were treated; 2. 62% of antenatal care attendees tested, all positive cases were treated; and 3. All antenatal care attendees tested and all positive cases were treated | One year or less | 1. Test 2. Staff 3. Treatment 4. Supplies/Consumables 5. Training | 1. Neonatal death 2. Still birth | total cost/DALY averted |

CEA: cost-effectiveness analysis; DALY: disability adjusted life year; dRDT: dual HIV and syphilis rapid diagnostic test; hRDT: HIV rapid diagnostic test; IEC: Information Education Communication; MDA: mass drug administration; nTrp: Non-treponemal; RST: rapid syphilis test; RPR: rapid plasma regain testing; TPHA: Treponema pallidum Hemagglutination Assay.

* Quality Control/Quality Assurance refers to reviewing the quality of all the factors required for effective testing and treatment for syphilis in pregnancy.

** Larson et al (2014) utilised country representative statistics, from a previously conducted evaluation study, to build their scenarios. Country statistics showed that 62% of antenatal clinic attendees were tested for syphilis while only 10% of the test positives were treated.

https://doi.org/10.1371/journal.pone.0253135.t003
| Author                  | Results                        | Cost-effectiveness decision rule                                                                 | Drivers of cost and cost-effectiveness       | Key findings                                      | Generalisability of results | percentage difference     |
|------------------------|--------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------|----------------------------|
| **Partial Economic Evaluations** |                                |                                                                                               |                                               |                                               |                             |                            |
| Shelley et al (2015) [64] | Pilot period                  | Average cost per woman tested and treated is lower than the baseline average cost per woman tested and treated (Pilot program) | 1. Cost (RST test kit)                        | RST rollout had higher costs than RST pilot   | Not stated                  | 105.5% (test); 135% (treated) |
|                        |                                |                                                                                               |                                               |                                               |                             |                            |
|                        | RST rollout                    | Average cost per woman tested and treated is lower than the baseline average cost per woman tested and treated (RST rollout) | 1. Screening coverage                         | RST had higher costs than RPR                | Not stated                  | 18.9% (test); 49.1% (treat) |
|                        |                                |                                                                                               | 2. Supply wastage                             |                                               |                             |                            |
|                        |                                |                                                                                               | 3. Time taken to test                         |                                               |                             |                            |
|                        | Obure et al (2017) [72] | RST*: Average Unit Cost/ woman tested: USD 10.26. Average Unit Cost/ woman treated: USD 15.89 RDT: Average Unit Cost/ woman tested: USD 15.89 | No sensitivity analysis                        | RST (and hRDT) had lower costs than dRDT     | Not stated                  | 43.1% (test); 101.4% (treat) |
|                        |                                |                                                                                               |                                               |                                               |                             |                            |
|                        | Levin et al (2007) [60]     | RPR: Average Unit Cost/ woman tested: USD 1.43 (Bolivia) and USD 0.91 (Mozambique) Average Unit Cost/ woman treated: USD 40.09 (Bolivia) and USD 12.25 (Mozambique) RST: Average Unit Cost/ woman tested: USD 1.91 (Bolivia) and USD 1.05 (Mozambique) Average Unit Cost/ woman treated: USD 40.77 (Bolivia) and USD 13.45 (Mozambique) | No sensitivity analysis                        | Mozambique: RST had higher costs than RPR Bolivia: RST had lower costs than RPR | Not stated                  | 28.7% (for testing in Bolivia) and 1.7% (for treating in Bolivia); 14.3% (for testing in Mozambique) and 9.3% (for treating in Mozambique) |

**Full Economic Evaluations** (Continued)
Table 4. (Continued)

| Author                     | Results                  | Cost-effectiveness decision rule                              | Drivers of cost and cost-effectiveness | Key findings                                      | Generalisability of results | percentage difference |
|----------------------------|--------------------------|----------------------------------------------------------------|----------------------------------------|--------------------------------------------------|----------------------------|------------------------|
| Bristow et al (2016) [73]  | hRDT only                | Incremental costs and DALYs is lower than the baseline (RST & hRDT; HIV only; hRDT & TPHA) | 1. Prevalence 2. Screening coverage 3. Risk of adverse outcome | dRDT had lower costs and was more effective than hRDT; hRDT; and RST; hRDT and TPHA in lab | Results generalisable in similar countries | 1.9% (Total Cost); 2% (DALYs) |
|                            | dRDT                    |                                                                   |                                        |                                                  |                            |                        |
|                            | hRDT and RST            |                                                                   |                                        |                                                  |                            |                        |
|                            | hRDT and TPHA           |                                                                   |                                        |                                                  |                            |                        |
| Owusu-Edusei et al (2011) [61] | Dual RST                | Cost-savings are greater than the baseline and overtreatment rates are lower than the baseline | 1. Cost (RST test kit) 2. Test sensitivity (performance) 3. Cost associated with adverse pregnancy outcomes | dRST had lower costs but was less effective than RST; dRST had lower costs and was more effective onsite RPR; RPR and TPHA (lab); no screening | Not stated | 33% (Total Cost); 183.1% (DALYs) |
|                            | RST                     |                                                                   |                                        |                                                  |                            |                        |
|                            | hRDT                    |                                                                   |                                        |                                                  |                            |                        |
|                            | RPR                     |                                                                   |                                        |                                                  |                            |                        |
|                            | Offsite (lab based) RPR and TPHA |                                                                   |                                        |                                                  |                            |                        |
|                            | No screening            |                                                                   |                                        |                                                  |                            |                        |
| Kuznik et al (2015) [65]  | No screening program: Average ICER as not reported for either Asia or Latin America RST: Asia: average ICER was USD 53/ DALY averted; and Latin America: average ICER was USD 60/ DALY averted | WHO threshold (ICER below country's Gross Domestic Product (GDP) per capita | Prevalence | RST cost-effective compared to comparator | Not stated | No baseline figure provided to calculate percentage difference |

(Continued)
Table 4. (Continued)

| Author | Results | Cost-effectiveness decision rule | Drivers of cost and cost-effectiveness | Key findings | Generalisability of results | percentage difference |
|--------|---------|----------------------------------|----------------------------------------|--------------|----------------------------|-----------------------|
| Terris-prestholt et al (2015) [69] | No screening program: ICER: Reported as not applicable Most cost-effective outcomes: 1. Peru: RST ICER was USD 53.69/ DALY averted; 2. Tanzania: MDA ICER was USD 8.7/ DALY averted; and 3. Zambia: MDA ICER was USD 5/ DALY averted | ICER is lower than the baseline scenario (no screening program) | 1. Cost (fixed clinic costs) 2. Screening coverage 3. RST reactivity rate 4. Antenatal clinic attendance | Peru: RST cost-effective compared to comparator; Tanzania: RST not as cost-effective as MDA; Zambia: RST not as cost-effective as MDA | Alludes to generalisability of results, but not definitively | 121.7% (for Peru); 167.5% (for Tanzania); 170.6 (for Zambia) |
| Kuznik et al (2013) [58] | No screening program: Average ICER was not reported RST Average ICER was USD 11/ DALY | Threshold of an ICER less than Gross National Income (GNI) per capita | Prevalence | RST cost-effective compared to comparator | Not stated | No baseline ICER provided to calculate percentage difference |
| Rydzak and Goldie (2008) [62] | No screening program • Discounted costs saved/1000 women: USD 110 220 RPR • Discounted costs saved/1000 women: USD 161 310 RST (dominates) • Discounted costs saved/1000 women: USD 170 030 | Cost-savings are greater than the baseline scenario (no screening program) | 1. Cost (labour, RST test kit price and other supplies) 2. Test sensitivity (performance) 3. Cost associated with adverse pregnancy outcomes | RST cost-effective compared to comparators | Results not generalisable to other settings or scenarios | 200% |
| Schackman et al (2007) [68] | Rural setting: RPR: ICER was USD 10.64/ DALY RST: ICER was USD 6.83/ DALY Urban setting: RST: ICER was USD 9.95/ DALY | Thresholds: 1. ICER lower than USD50/ DALY recommended for health interventions in resource- poor countries; and 2. ICER lower than the GDP per capita of country where intervention is being implemented | 1. Prevalence 2. Test sensitivity (performance) | RST cost-effective compared to comparators | Results generalisable to HIV scale-up in resource poor settings | No baseline ICER provided to calculate percentage difference |
| Vickerman et al (2006) [70] | Test using serum: RPR • Cost/DALY: USD 12/ DALY RST (Determine) • Cost/DALY: USD 17/ DALY Test using whole blood: RPR • Cost/DALY: USD 16.8/ DALY RST (Determine) • Cost/DALY: USD 14.1/ DALY | Threshold cost-effectiveness ratio is lower than the baseline (RPR test) | Test sensitivity (performance) | RST cost-effective compared to comparators | Not stated | 19.2% (using serum) and 32.5% (using whole blood) |

(Continued)
Table 4. (Continued)

| Author                  | Results                                                                                     | Cost-effectiveness decision rule                                                                 | Drivers of cost and cost-effectiveness                                                                 | Key findings                                                                 | Generalisability of results | percentage difference |
|-------------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------|------------------------|
| Blandford et al (2007) [59] | Off-site RPR and confirmatory TPHA • Cases averted: 18 • Cost/case averted: USD 82 per case. Onsite RPR • Cases averted: 16 • Cost/case averted: not published (but states “dominated” RST • Cases averted: 27 • Cost/case averted: USD104 per case. | ICER is lower than the baseline scenario (no screening program)                                    | 1. Prevalence 2. Test sensitivity (performance) 3. Relative distribution of active/latent syphilis     | RST cost-effective compared to comparators                                  | Not stated                  | 33.8%                  |
| Mallma et al (2016) [67] | RST • Cost/DALY averted: USD 109/ DAILY averted RPR • Cost/DALY averted: USD 46/ DALY averted | WHO threshold (ICER is below the country’s GDP per capita)                                        | 1. Prevalence 2. Cost (salaries) 3. Test positivity rates 4. Screening coverage 5. Number of hours worked | RST cost-effective compared to comparator                                    | Not stated                  | 81.3%                  |
| Romoren et al (2007) [74] | Syndromic Management • Cases cured (erythromycin): 800 • Cost/ cured case (erythromycin): USD 66 • Cases cured (azithromycin): 1500 • Cost/ cured case (azithromycin): USD 21 point-of-care test (0.75 sensitivity- base case) • Cases cured (erythromycin): 3200 • Cost/ cured case (erythromycin): USD 35 • Cases cured (azithromycin): 3500 • Cost/ cured case (azithromycin): USD 31 | Willingness-to-pay threshold (cost-effectiveness ratio is lower than the willingness to pay threshold) | 1. Prevalence 2. Cost (point-of-care test) 3. Test sensitivity (performance) 4. Probability of partner notification | point-of-care test combined with Azithromycin treatment cost-effective compared to comparators | Results generalisable to other sub-Saharan countries | 62.5% (using erythromycin) and 94.9% (using azithromycin) |
| Larson et al (2014) [66] | Evaluation study conditions (62% of antenatal clinic (ANC) attendees tested and 10% of positive cases treated): • USD628/ DAILY averted 62% of ANC attendees tested, and all positive cases treated: • USD66/ DAILY averted All ANC attendees tested, and all positive cases treated: • USD60/ DAILY averted | ICER is lower than the baseline scenario                                                              | 1. Prevalence 2. Cost (training) 3. Number of antenatal clinic attendees tested and treated 4. Staff time | RST (testing and treating all antenatal clinic attendees) cost-effective compared to comparators | Results not generalisable to other settings or scenarios | 165.1%                  |

ANC: Antenatal clinic; CEA: cost-effectiveness analysis; DALY: Disability-adjusted-life-years; GDP: Gross domestic product; GNI: Gross national income; dRDT: dual HIV and syphilis rapid diagnostic test; hRDT: HIV rapid diagnostic test; ICER: Incremental cost effectiveness ratio; IEC: Information Education Communication; MDA: mass drug administration; nTrp: Non-treponemal; RST: rapid syphilis test; RPR: rapid plasma regain testing; WHO: World Health Organization.

a. Only syphilis was included in the analysis, results for HIV were excluded.
b. Did not publish an ICER (or Cost/DALY) as the difference between each comparator would be smaller than 1, and therefore not significant.
c. Did not publish an ICER (or Cost/DALY), as it may not have yielded a meaningful outcome.
d. Reported average ICERS.

https://doi.org/10.1371/journal.pone.0253135.t004
univariate sensitivity analysis and of those studies, six conducted a multivariate sensitivity analysis [39, 61, 63, 64, 68, 73] and three conducted a probabilistic sensitivity analysis [38, 69, 71] in addition to the univariate sensitivity analysis. The main drivers for costs and cost effectiveness are illustrated in Table 4 and included: STI prevalence [58, 59, 65–69, 71, 73], cost of test, cost of treatment, cost of training or salaries and wages [58, 61, 62, 64, 66–69, 71], test sensitivity and specificity [58, 59, 61, 62, 68, 70, 71], and treatment and/or screening coverage [63, 64, 66, 69, 73].

Quality appraisal

All studies met 75% or more of the methodology criteria of the Drummond Checklist and 60% for the CHEERS checklist (Fig 3). Fig 3 illustrates the shortcomings with respect to reporting criteria in the reviewed papers. The appraisal based on the Drummond checklist (Table 5), indicated that a key gap was the reporting of all relevant costs with few studies taking account of training, quality control and quality assurance. The appraisal using the CHEERS checklist (Table 6) highlighted that only half the studies (n = 8) clearly outlined the time horizon for the

Fig 2. Economic evaluation comparators for point-of-care testing and treatment for STIs in pregnancy in LMIC. MDA: Mass Drug Administration; POC: point-of-care.

https://doi.org/10.1371/journal.pone.0253135.g002

Fig 3. Assessment of methodological and reporting quality of economic evaluations of point-of-care testing and treatment for STIs in pregnancy in LMIC ( ).

https://doi.org/10.1371/journal.pone.0253135.g003
analysis [59, 61–64, 66, 71, 72], most taking a one year or shorter time horizon [59, 63, 64, 66, 71, 72]. Half the studies (n = 8) utilised analytical methods to deal with missing values and uncertainty [58, 61, 63, 65, 67, 68, 70, 71]. Only a third of the studies (n = 6) explained variations in the data by different population characteristics [60, 64, 67, 70–72]. The most common sub-group analyses were by type or location of health facility (hospital or health centre and urban or rural).

### Discussion

This review identified 16 economic evaluations set in LMIC on point-of-care testing and treatment for STIs in pregnancy and presented a synthesis of the evidence. All but one study focused on syphilis and most were set in African countries. The majority of studies in this review suggest that point-of-care testing and treatment for syphilis and CT in pregnancy can be cost-effective in LMIC settings when compared to no screening programs, laboratory-based testing and/or syndromic management. These studies also indicate that point-of-care testing and treatment for STIs is most cost-effective where access to alternative testing mechanisms is limited, including laboratory testing facilities. Further, there was considerable variation in the types of costs and outcomes utilised by economic evaluations, as well as in the time horizons and sample sizes, which proved to be a challenge in comparing the costs and cost effectiveness of interventions across the different settings. The decision rules for cost-effectiveness and percentage differences in Table 4 demonstrate the between study variation. The decision rules indicate that cost-effectiveness is dependent upon the decision rule utilised. Further, percentage difference highlights the difference between the largest and smallest cost-effectiveness measures per study. The largest percentage difference between comparators was 170% [69] while the smallest 19% [70], which demonstrates the large variability with respect to measures of cost-effectiveness. Key drivers of cost and cost-effectiveness were STI prevalence and costs (including the cost of tests, treatment, training costs, and salaries or wages).

Our review also highlighted some gaps in the evidence, in terms of methodology and scope. First, the evidence is limited both in geographic and infection scope. Most studies were
conducted on the African continent, with only one study conducted in Asia [65] and none in the Pacific. Further, point-of-care testing and treatment for syphilis in pregnancy dominated the literature. Only one economic evaluation focussed on CT and there were no economic evaluations of other prevalent, curable STIs such as NG, TV or BV. The lack of studies from Asia-Pacific countries is of concern given the high STI prevalence, particularly for common infections including syphilis, NG, TV, CT, reported among pregnant women in the region [68, 72, 75] as well as the widespread integration of point-of-care testing and treatment for syphilis in antenatal clinics [22]. Although existing economic evaluations provide guidance to cost-effectiveness, context matters. In particular, results from economic evaluations cannot always be generalised because local disease epidemiology, social, cultural and financial barriers to implementation vary between settings [76]. These could lead to differences in the uptake of testing and treatment between settings, and therefore, also differences in the cost of scale up.

Table 6. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist.

| Section/Item (including item number) on CHEERS checklist | References |
|---------------------------------------------------------|------------|
| Title and abstract                                       | [65] [69] [58] [62] [68] [70] [59] [67] [71] [66] [64] [63] [72] [60] [73] [61] |
| 1 Title                                                 | Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y |
| 2 Abstract                                              | Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y |
| Introduction                                             | Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y |
| Methods                                                 | Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y |
| 4 Target pop. & sub-groups                              | NA NA NA NA NA NA Y NA NA NA NA NA NA NA NA |
| 5 Setting and location                                   | Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y |
| 6 Study perspective                                     | Y Y Y Y Y N Y N Y Y Y Y Y Y Y Y |
| 7 Comparators                                           | Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y |
| 8 Time horizon                                          | Y N N Y N N Y N Y Y Y Y Y N N Y |
| 9 Discount rate                                         | Y Y Y Y Y N N Y N Y Y Y Y Y Y Y |
| 10 Health outcomes                                      | Y Y Y Y Y Y Y Y Y Y N N N N Y Y |
| 11a Effectiveness measures: single-study estimates      | NA Y NA NA NA NA Y NA NA NA NA NA NA NA NA NA |
| 11b Effectiveness measures: synthesis-based estimates   | Y NA Y Y Y NA Y N Y Y NA NA NA NA NA NA NA |
| 12 Preference based outcome measurement/valuation       | Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y |
| 13a Resource/Cost estimates: single study-based         | Y NA NA NA NA NA NA Y NA NA Y Y Y NA NA |
| 13b Resource/Cost estimates: model-based                | NA Y Y Y Y Y NA NA NA NA NA NA NA Y Y |
| 14 Currency, price data and conversion                  | Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y |
| 15 Model choice                                         | Y N Y Y Y N Y N Y Y Y Y Y Y Y Y |
| 16 Assumptions                                          | N N Y Y Y Y Y Y Y Y Y Y Y N Y Y |
| 17 Analytical methods                                   | Y N Y N Y Y N Y N Y N N N N Y Y |
| Results                                                 | Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y |
| 18 Study parameters                                     | Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y |
| 19 Incremental costs and outcomes                       | Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y |
| 20a Characterising uncertainty: single study-based      | Y Y Y Y Y Y Y Y Y Y NA NA Y Y Y N Y Y |
| 20b Characterising uncertainty: model-based             | NA NA NA NA NA NA NA NA NA NA NA NA NA NA |
| 21 Characterising heterogeneity                          | N N N N N Y N Y Y N N Y Y N N |
| Discussion                                              | Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y |
| Other                                                   | Y Y Y Y N Y Y Y Y Y Y Y Y Y N |
| 23 Funding source                                       | Y Y Y N Y Y Y Y Y Y Y Y Y N |
| 24 Conflicts of interest                                | Y Y Y N Y Y N Y Y Y Y Y Y N |

Y: Yes (included in the article); N: No (Not included in the article); NA: Not applicable (not applicable to the type of study).

https://doi.org/10.1371/journal.pone.0253135.t006
In the last decade, the number of studies based in LMICs evaluating the utility of point-of-care tests for the detection and treatment of STIs in pregnancy has increased [38, 77], which has influenced the number of economic evaluations conducted on these types of tests. Yet with few cheap, accurate and easy to use point-of-care tests for CT, NG, TV and BV available [78], there have not been many effectiveness trials conducted in LMIC. As such, the data available to conduct robust economic evaluations is limited. Therefore, there is a need to expand the scope of effectiveness studies and accompanying economic evaluations of point-of-care testing for high-burden STIs in pregnancy [38, 79, 80].

Second, most studies included in this review took the provider perspective. Only three studies took a societal perspective. The paucity of studies conducted from the societal perspective potentially excludes and/or underestimates the direct and indirect costs to women such as reducing patient waiting times and reducing the number of clinic visits required to receive results, which in turn is expected to reduce the considerable direct and indirect costs incurred by many women seeking antenatal care in LMICs [81, 82]. Consequently, these direct and indirect costs can be, in many settings, barriers to participation as costs are often borne to the patient as OOP expenses and can lead to catastrophic health expenditure, which might lead to a drop in uptake/participation.

Third, most economic evaluations reviewed had short time horizons of 12 months or less. Short time horizons do not consider the lifetime implications of effective point-of-care testing and treatment of STIs in pregnancy. Economic evaluations in this field should ideally incorporate the long-term costs and benefits to both mother and baby from adopting point-of-care testing in order to capture said costs and benefits that occur later in life.

Our review indicated that all but two studies conducted a sensitivity analysis, which demonstrate the variables that drive costs and cost-effectiveness in each study. The most common drivers of cost and cost-effectiveness were STI prevalence and costs (which included the cost of tests, treatment, training costs, and salaries or wages). The sensitivity analyses of the studies included in this review did not explore the potential variation in loss-to-follow-up. These findings are consistent with other systematic reviews that have indicated that HIV prevalence and the cost of the HIV test are key drivers of cost-effectiveness of HIV screening in pregnancy [83] and key populations, such as sex workers [84].

We also found that most studies applied a narrow definition to the costs of point-of-care testing including only the cost of test kits, treatment costs and staff salaries. Costs associated with other core activities such as quality control, quality assurance and procurement are not negligible, and thus these studies may have underestimated the true cost of POC testing [85]. Underestimating costs leads to inaccurate projected costs for implementation and scale up, which consequently means that insufficient budget will be allocated to the implementation and scale up of the intervention. Insufficient funding, will inevitably mean that scale up will not go as planned, may be suspended, or may not run successfully [45]. Standardising the methodology, or introducing guidelines, for measuring costs may mitigate the likelihood that crucial costs are excluded from analyses. In addition, this will aid the comparison of costs across studies, which was particularly difficult in this review.

Finally, increased attention should also be paid to the broader issues of affordability and equity. Despite recent recommendations by the International Society for Pharmacoeconomics and Outcomes Research to conduct budget impact analyses alongside economic evaluations [45], no studies in this review did so although two did mention its importance [58, 62]. Budget impact analyses explore economic and financial consequences highlighting the affordability of program implementation. They specifically factor in short-run costs to cater for government budget allocations [45, 86] and are especially relevant in settings where health care resources are highly constrained [49]. There have been ongoing calls for incorporating equity within
economic evaluations of health interventions [46, 48]. This is particularly relevant for point-of-care testing and treatment, which can reduce inequalities in healthcare by diagnosing and treating STIs in a single visit to a health facility. This is important in populations with limited access to laboratory facilities [87]. Future studies in this field should explore ways to expand cost-effectiveness analysis to address health equity concerns including distributional cost-effectiveness analysis which quantifies the distribution of costs and effects by equity-relevant variables such as socioeconomic status, location, ethnicity, sex and severity of illness [88]. Alternatively, non-health benefits such as financial risk protection could be measured using extended cost-effectiveness analysis [47, 89].

Economic evaluations generate evidence to optimally allocate resources and provide the foundation for the delivery of healthcare interventions [55]. This review has highlighted that point-of-care testing for STIs in pregnancy has proven to be cost effective in African settings. The results may be generalisable to similar settings, however consideration should be taken with the shortcomings revealed by this review, including the heterogenous nature of economic evaluations, the perspective taken and the short run time horizons. Suggesting that evidence should be interpreted with caution, and an economic evaluation conducted prior to implementing programmes to fill these gaps and provide better information to aid uptake, scale up and indicate priority settings in resource constrained contexts. Going forward, extended cost-effectiveness analyses and budget impact analyses provide evidence for the implementation of a cost-effective intervention, which is equitable, affordable, and sustainable. Extended cost-effectiveness analyses highlight the distributional effects within a given populations as a result of the implementation of an intervention; while budget impact analyses determine the investment required by the government to implement an intervention; and demonstrate affordability given available resources and budget constraints.

This review has some limitations, with respect to the synthesis of key results, the significant variability in economic methods, particularly regarding the types of costs and outcomes measured, meant that the planned meta-analysis was not possible [54]. Further, few studies utilised a societal perspective to determine costs, which may have understated the true value associated with point-of-care testing and treatment for STIs in pregnancy. However, the descriptive and narrative synthesis provides valuable insight into these limitations and gaps and suggests direction for future research. Additionally, most studies took a narrow view of costs and measured them along a short-run time horizon, which highlights a short-coming of the studies included in this review. This systematic review did not include grey literature, which can also be an important source of evidence but less likely to be subject to independent scientific peer-review, where additional bias is introduced. Finally, a further enhancement of economic evaluations would be the inclusion of equity and affordability analyses.

**Conclusion**

Our review indicates that point-of-care testing and treatment for syphilis in pregnancy is cost-effective in LMICs compared to laboratory-based testing, syndromic management and where no testing programs have been implemented. The review also revealed that key drivers of cost and cost-effectiveness are STI prevalence and costs (including the cost of tests, treatment, training costs, and salaries or wages. It also highlights important gaps in the published literature that requires urgent attention by researchers. These gaps include broadening the scope of economic evaluations to include common curable STIs, such as CT, NG, TV and BV; the geographical representation of studies; the costs borne to pregnant women and their families as a result of accessing testing and treatment for STIs; the life time costs and effects of testing and treatment on mothers and their babies and finally; the budget and equity
implications of implementing point-of-care testing and treatment versus other screening practices.

Supporting information

S1 File. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.
(DOCX)

S1 Dataset.
(XLSX)

Author Contributions

Conceptualization: Olga P. M. Saweri, Neha Batura, Rabiah Al Adawiyah, Louise M. Causer, William S. Pomat, Andrew J. Vallely, Virginia Wiseman.

Data curation: Olga P. M. Saweri, Neha Batura, Louise M. Causer.

Formal analysis: Olga P. M. Saweri, Neha Batura, Louise M. Causer, Virginia Wiseman.

Funding acquisition: William S. Pomat, Andrew J. Vallely.

Investigation: Olga P. M. Saweri, Neha Batura, Rabiah Al Adawiyah, William S. Pomat, Andrew J. Vallely, Virginia Wiseman.

Methodology: Olga P. M. Saweri, Neha Batura, Louise M. Causer, Virginia Wiseman.

Project administration: Olga P. M. Saweri, Neha Batura, Andrew J. Vallely, Virginia Wiseman.

Resources: William S. Pomat, Andrew J. Vallely, Virginia Wiseman.

Software: Olga P. M. Saweri, Neha Batura.

Supervision: Olga P. M. Saweri, Andrew J. Vallely, Virginia Wiseman.

Validation: Andrew J. Vallely, Virginia Wiseman.

Visualization: Olga P. M. Saweri, Neha Batura, Rabiah Al Adawiyah.

Writing – original draft: Olga P. M. Saweri, Neha Batura, Louise M. Causer, Virginia Wiseman.

Writing – review & editing: Olga P. M. Saweri, Neha Batura, Rabiah Al Adawiyah, Louise M. Causer, William S. Pomat, Andrew J. Vallely, Virginia Wiseman.

References

1. Adachi K., Nielsen-Saines K., and Klausner J.D., Chlamydia trachomatis Infection in Pregnancy: The Global Challenge of Preventing Adverse Pregnancy and Infant Outcomes in Sub-Saharan Africa and Asia. Biomed Res Int., 2016. 2016: p. 21. https://doi.org/10.1155/2016/9315757 PMID: 27144177

2. Saleska J.L., et al., Use of Antiretroviral Therapy During Pregnancy and Adverse Birth Outcomes Among Women Living With HIV-1 in Low- and Middle-Income Countries: A Systematic Review. J Acquir Immune Defic Syndr, 2018. 79(1): p. 1–9. https://doi.org/10.1097/QAI.0000000000001770 PMID: 29847475

3. Shava E., et al., High rates of adverse birth outcomes in HIV and syphilis co-infected women in Botswana. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2019: p. 1.

4. Newman L., et al., Global Estimates of Syphilis in Pregnancy and Associated Adverse Outcomes: Analysis of Multinational Antenatal Surveillance Data. PLOS Medicine, 2013. 10(2): p. e1001396. https://doi.org/10.1371/journal.pmed.1001396 PMID: 23468598
5. Dingens A.S., et al., Bacterial vaginosis and adverse outcomes among full-term infants: a cohort study. BMC pregnancy and childbirth, 2016. 16(1): p. 278–278. https://doi.org/10.1186/s12884-016-1073-y PMID: 27658456

6. Olaleye A.O., et al., Sexually transmitted infections in pregnancy—An update on Chlamydia trachomatis and Neisseria gonorrhoeae. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2020. 255: p. 1–12. https://doi.org/10.1016/j.ejogrb.2020.10.002 PMID: 33059307

7. Olson-Chen C., Balaram K., and Hackney D.N., Chlamydia trachomatis and Adverse Pregnancy Outcomes: Meta-analysis of Patients With and Without Infection. Maternal and Child Health Journal, 2018. 22(6): p. 812–821. https://doi.org/10.1007/s10995-018-2451-z PMID: 29417367

8. Konadu D.G., et al., Prevalence of vulvovaginal candidiasis, bacterial vaginosis and trichomoniasis in pregnant women attending antenatal clinic in the middle belt of Ghana. BMC Pregnancy and Childbirth, 2019. 19(1): p. 341. https://doi.org/10.1186/s12884-019-2488-z PMID: 31547803

9. Valleye L.M., et al., Adverse pregnancy and neonatal outcomes associated with &lt;em&gt;Neisseria gonorrhoeae, Mycoplasma genitalium, M. hominis, Ureaplasma urealyticum and U. parvum:&lt;/em&gt; a systematic review and meta-analysis protocol. BMJ Open, 2018. 8(11): p. e024175. https://doi.org/10.1136/bmjopen-2018-024175 PMID: 30498048

10. Korenromp E.L., et al., Global burden of maternal and congenital syphilis and associated adverse birth outcomes—Estimates for 2016 and progress since 2012. PLOS ONE, 2019. 14(2): p. e0211720. https://doi.org/10.1371/journal.pone.0211720 PMID: 30811406

11. Joseph Davey D.L., et al., Prevalence of Curable Sexually Transmitted Infections in Pregnant Women in Low- and Middle-Income Countries From 2010 to 2015: A Systematic Review. Sexually transmitted diseases, 2016. 43(7): p. 450–458. https://doi.org/10.1097/OLQ.0000000000000460 PMID: 27322048

12. WHO, Sexually Transmitted Infections (STIs): The importance of a renewed commitment to STI prevention and control in achieving global sexual and reproductive health. 2012. WHO: Geneva, Switzerland. p. 8.

13. Mullick S., et al., Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. Sexually Transmitted Infections, 2005. 81(4): p. 294–302. https://doi.org/10.1136/sti.2002.040077 PMID: 16061534

14. Rowley J., et al., Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ, 2019. 97(8): p. 548–562p. https://doi.org/10.1097/BLT.18.228486 PMID: 31384073

15. Gomez G.B., et al., Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis. Bulletin of the World Health Organization, 2013. 91(3): p. 217–226. https://doi.org/10.2471/BLT.12.107623 PMID: 23476094

16. Johnson H.L., et al., Sexually Transmitted Infections and Adverse Pregnancy Outcomes Among Women Attending Inner City Public Sexually Transmitted Diseases Clinics. Sexually Transmitted Diseases, 2011. 38(3): p. 167–171. https://doi.org/10.1097/OLQ.0b013e3181ee85f PMID: 20852454

17. Hawkes S, M.N., Broutet N, Low N, Effectiveness of interventions to improve screening for syphilis in pregnancy: a systematic review and meta-analysis Lancet Infect Dis, 2011. 11(9): p. 684–91. https://doi.org/10.1016/S1473-3099(11)70104-9 PMID: 21683653

18. Moodley T., et al., Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa. BMC Pregnancy and Childbirth, 2016. 16(1): p. 35. https://doi.org/10.1186/s12884-016-0821-3 PMID: 26867536

19. Chagomerana M.B., et al., Optimizing prevention of HIV mother to child transmission: Duration of antiretroviral therapy and viral suppression at delivery among pregnant Malawian women. PLOS ONE, 2018. 13(4): p. e0195033. https://doi.org/10.1371/journal.pone.0195033 PMID: 29614083

20. Swartzendruber A., et al., Introduction of rapid syphilis testing in antenatal care: A systematic review of the impact on HIV and syphilis testing uptake and coverage. International Journal of Gynaecology & Obstetrics, 2015. 130 Suppl 1: p. S15–21. https://doi.org/10.1016/j.ijgo.2015.04.008 PMID: 26001704

21. WHO, Pregnancy, childbirth, postpartum and newborn care: a guide for essential practice. 2015. WHO. p. 184.

22. WHO, WHO Guideline on: Syphilis screening and treatment for pregnant women. 2017. WHO.

23. WHO WHO recommendation on sexually transmitted infections testing in pregnancy. 2016. WHO: Geneva.

24. World Health Organization. Regional Office for the Western P., Regional framework for the triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis in Asia and the Pacific, 2018–2030. 2018. Manila: WHO Regional Office for the Western Pacific.

25. WHO, Sexually transmitted and other reproductive tract infections. 2005: Geneva.
26. Moodley D., et al., High Prevalence and Incidence of Asymptomatic Sexually Transmitted Infections During Pregnancy and Postdelivery in KwaZulu Natal, South Africa. Sexually Transmitted Diseases, 2015. 42(1). https://doi.org/10.1097/OLQ.0000000000000219 PMID: 25504300

27. Kaida A., et al., A high burden of asymptomatic genital tract infections undermines the syndromic management approach among adolescents and young adults in South Africa: implications for HIV prevention efforts. BMC Infectious Diseases, 2018. 18(1): p. 499. https://doi.org/10.1186/s12879-018-3380-6 PMID: 30285705

28. Garrett N.J., McGrath N., and Mindel A., Advancing STI care in low/middle-income countries: has STI syndromic management reached its use-by date? Sexually Transmitted Infections, 2017. 93(1): p. 4–5. https://doi.org/10.1136/sxtrans-2016-052581 PMID: 27084840

29. Herring A., et al., Evaluation of rapid diagnostic tests: syphilis. Nature Reviews Microbiology, 2006. 4 (12): p. S33–S40. https://doi.org/10.1038/nrmicro1563 PMID: 1736685

30. Peeling R. and Ye H., Peeling R. W. & Ye H. Diagnostic tools for preventing and managing maternal and congenital syphilis: an overview. Bull. World Health Organ. 82, 439–446. Bulletin of the World Health Organization, 2004. 82: p. 439–46. PMID: 15356937

31. Cristillo A.D., et al., Point-of-Care Sexually Transmitted Infection Diagnostics: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Programmatic Meeting. Sexually Transmitted Diseases, 2017. 44(4): p. 211–218. https://doi.org/10.1097/OLQ.0000000000000572 PMID: 28282646

32. WHO, Guidelines for the management of sexually transmitted infections. 2003. WHO. https://doi.org/10.1136/sti.79.2.111 PMID: 12690130

33. WHO, Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus, Magnus Unemo R.B., Catherine Ison, David Lewis, Francis Ndowa, Rosanna Peeling, Editor. 2013, WHO: Geneva.

34. WHO, Point-Of-Care Diagnostic Tests (POCTs) for Sexually Transmitted Infections (STIs). 2018 19/11/2018; Available from: https://www.who.int/reproductivehealth/topics/rtis/poc.ts/en/.

35. Peeling R.W. and Mabey D., Point-of-care tests for diagnosing infections in the developing world. Clinical Microbiology & Infection, 2010. 16(8): p. 1062–9. https://doi.org/10.1111/j.1469-0691.2010.03279.x PMID: 20670288

36. Guy R.J., et al., Molecular point-of-care testing for chlamydia and gonorrhoea in Indigenous Australians attending remote primary health services (TTANGO): a cluster-randomised, controlled, crossover trial. The Lancet Infectious Diseases, 2018. 18(10): p. 1117–1126. https://doi.org/10.1016/S1473-3099(18)30429-8 PMID: 30303108

37. Morris S.R., et al., Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study. Lancet Infect Dis, 2020. https://doi.org/10.1016/S1473-3099(20)30734-9 PMID: 33242473

38. Badman S.G., et al., A novel point-of-care testing strategy for sexually transmitted infections among pregnant women in high-burden settings: results of a feasibility study in Papua New Guinea. BMC infectious diseases, 2016. 16: p. 250–250. https://doi.org/10.1186/s12879-016-1573-4 PMID: 27268218

39. Mabey D.C., et al., Point-of-Care Tests to Strengthen Health Systems and Save Newborn Lives: The Case of Syphilis. PLOS Medicine, 2012. 9(6): p. e1001233. https://doi.org/10.1371/journal.pmed.1001233 PMID: 22719229

40. Marks M. and Mabey D.C., The introduction of syphilis point of care tests in resource limited settings. Expert review of molecular diagnostics, 2017. 17(4): p. 321–325. https://doi.org/10.1080/14737159.2017.1303379 PMID: 28266230

41. Gaydos C.A., et al., Performance of the Cepheid CT/NG Xpert Rapid PCR Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. Journal of clinical microbiology, 2013. 51(6): p. 1666–1672. https://doi.org/10.1128/JCM.03461-12 PMID: 23467600

42. Heller P.S., The prospects of creating ‘fiscal space’ for the health sector. Health Policy Plan, 2006. 21 (2): p. 75–9. https://doi.org/10.1093/heapol/czj013 PMID: 16415338

43. Fleming K.A., et al., An Essential Pathology Package for Low- and Middle-Income Countries. American Journal of Clinical Pathology, 2017. 147(1): p. 15–32. https://doi.org/10.1093/ajcp/aqw143 PMID: 28158414

44. Toliman P., et al., Field Evaluation of Xpert HPV Point-of-Care Test for Detection of Human Papillomavirus Infection by Use of Self-Collected Vaginal and Clinician-Collected Cervical Specimens. Journal of clinical microbiology, 2016. 54(7): p. 1734–1737. https://doi.org/10.1128/JCM.00529-16 PMID: 27076663

45. Bilinski A., et al., When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. PLOS Medicine, 2017. 14(10): p. e1002397. https://doi.org/10.1371/journal.pmed.1002397 PMID: 28968399
46. Cookson R., et al., Health equity monitoring for healthcare quality assurance. Social Science & Medicine, 2018. 198: p. 148–156. https://doi.org/10.1016/j.socscimed.2018.01.004 PMID: 29335161

47. Verguet S., Kim J.J., and Jamison D.T., Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. PharmacoEconomics, 2016. 34(9): p. 913–923. https://doi.org/10.1007/s40273-016-0414-z PMID: 27374172

48. Cookson R., et al., Using Cost-Effectiveness Analysis to Address Health Equity Concerns. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2017. 20(2): p. 206–212. https://doi.org/10.1016/j.jval.2016.11.027 PMID: 28237196

49. Wiseman V., et al., Using Economic Evidence to Set Healthcare Priorities in Low-Income and Lower-Middle-Income Countries: A Systematic Review of Methodological Frameworks. Health Economics, 2016. 25(S1): p. 140–161. https://doi.org/10.1002/hec.3299 PMID: 26804361

50. UNDP, Transforming our world: the 2030 agenda for sustainable development. 2015.

51. St John A. and Price C.P., Economic Evidence and Point-of-Care Testing. The Clinical biochemist. Reviews, 2013. 34(2): p. 61–74. PMID: 24151342

52. Drummond M.F. and Jefferson T.O., Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ (Clinical research ed.), 1996. 313(7052): p. 275–283. https://doi.org/10.1136/bmj.313.7052.275 PMID: 8704542

53. Husereau D., et al., Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 2013. 16(2): p. 231–250. https://doi.org/10.1016/j.jval.2013.02.002 PMID: 23538175

54. Saweri O.P.M., et al., Cost and cost-effectiveness of point-of-care testing and treatment for sexually transmitted and genital infections in pregnancy in low-income and middle-income countries: a systematic review protocol. BMJ Open, 2019. 9(11): p. e029945. https://doi.org/10.1136/bmjopen-2019-029945 PMID: 31727649

55. Drummond M.F., et al., Methods for the Economic Evaluation of Health Care Programmes. 1997, Oxford: Oxford University Press.

56. The World Bank Group. Low and Middle Income Country Classification. 2018 19/11/2018]; Available from: https://data.worldbank.org/income-level/low-and-middle-income?view=chart.

57. Ryan R; Cochrane Consumers and Communication Review Group. Data synthesis and analysis. 2013 [cited June 2013 4th March 2020]; Available from: https://cccrg.cochrane.org/sites/cccrg.cochrane.org/files/public/uploads/AnalysisRestyled.pdf.

58. Kuznik A., et al., Antenatal syphilis screening using point-of-care testing in Sub-Saharan African countries: a cost-effectiveness analysis. PLoS Medicine / Public Library of Science, 2013. 10(11): p. e1001545. https://doi.org/10.1371/journal.pmed.1001545 PMID: 24223524

59. Blandford J.M., et al., Cost-effectiveness of on-site antenatal screening to prevent congenital syphilis in rural eastern Cape Province, Republic of South Africa. Sexually Transmitted Diseases, 2007. 34(7 Suppl): p. S61–6. https://doi.org/10.1097/01.olq.0000258314.20752.5f PMID: 17308502

60. Levin C.E., et al., Analysis of the operational costs of using rapid syphilis tests for the detection of maternal syphilis in Bolivia and Mozambique. Sexually Transmitted Diseases, 2007. 34(7 Suppl): p. S47–54. https://doi.org/10.1097/01.olq.0000245986.62775.b6 PMID: 17220812

61. Owusu-Eduose K. Jr, Gift T.L., and Ballard R.C., Cost-effectiveness of a dual non-treponemal/treponemal syphilis point-of-care test to prevent adverse pregnancy outcomes in Sub-Saharan Africa. Sexually Transmitted Diseases, 2011. 38(11): p. 997–1003. https://doi.org/10.1097/OLQ.0b013e3182260987 PMID: 21992974

62. Rydzak C.E. and Goldie S.J., Cost-effectiveness of rapid point-of-care prenatal syphilis screening in sub-Saharan Africa. Sexually Transmitted Diseases, 2008. 35(9): p. 775–784. https://doi.org/10.1097/OLQ.0b013e318176196d PMID: 18607319

63. Sweeney S., et al., The costs of accessible quality assured syphilis diagnostics: informing quality systems for rapid syphilis tests in a Tanzanian setting. Health policy and planning, 2014. 29(5): p. 633–641. https://doi.org/10.1093/heapol/czt049 PMID: 23894075

64. Shelley K.D., et al., Scaling Down to Scale Up: A Health Economic Analysis of Integrating Point-of-Care Syphilis Testing into Antenatal Care in Zambia during Pilot and National Rollout Implementation. Plos One, 2015. 10(5): p. 19. https://doi.org/10.1371/journal.pone.0125675 PMID: 25970443

65. Kuznik A., et al., Antenatal syphilis screening using point-of-care testing in low- and middle-income countries in Asia and Latin America: a cost-effectiveness analysis. PLoS ONE [Electronic Resource], 2015. 10(5): p. e0127379. https://doi.org/10.1371/journal.pone.0127379 PMID: 26010366

66. Larson B.A., et al., Finding a needle in the haystack: the costs and cost-effectiveness of syphilis diagnosis and treatment during pregnancy to prevent congenital syphilis in Kalomo District of Zambia. PLoS
67. Mallma P., et al., Rapid Syphilis Testing Is Cost-Effective Even in Low-Prevalence Settings: The CISNE-PERU Experience. Plos One, 2016. 11(3): p. 11. https://doi.org/10.1371/journal.pone.0149568

PMID: 26920867

68. Schackman B.R., et al., Cost-effectiveness of rapid syphilis screening in prenatal HIV testing programs in Haiti. PLoS Medicine / Public Library of Science, 2007. 4(5): p. e183.

69. Terris-Prestholt F., et al., The cost-effectiveness of 10 antenatal syphilis screening and treatment approaches in Peru, Tanzania, and Zambia. International Journal of Gynecology and Obstetrics, 2015. 130(S1): p. S73–S80.

70. Vickerman P., et al., Modelling the cost-effectiveness of introducing rapid syphilis tests into an antenatal syphilis screening programme in Mwanza, Tanzania. Sexually Transmitted Infections, 2006. 82 Suppl 5: p. v38–43. https://doi.org/10.1136/sti.2006.021824 PMID: 17215276

71. Romoren M., et al., Costs and health consequences of chlamydia management strategies among pregnant women in sub-Saharan Africa. Sexually Transmitted Infections, 2007. 83(7): p. 558–66. https://doi.org/10.1136/sti.2007.026930 PMID: 17932126

72. Obure C.D., et al., A comparative analysis of costs of single and dual rapid HIV and syphilis diagnostics: Results from a randomised controlled trial in Colombia. Sexually Transmitted Infections, 2017. 93(7): p. 482–486. https://doi.org/10.1136/sextrans-2016-052961 PMID: 28496681

73. Bristow C.C., et al., Cost-effectiveness of HIV and syphilis antenatal screening: a modelling study. Sex Transm Infec, 2016. 92(5): p. 340–6. https://doi.org/10.1136/sextrans-2015-052367 PMID: 26920867

74. Romoren M., et al., Chlamydia and gonorrhoea in pregnant Batswana women: time to discard the syndromic approach? BMC Infectious Diseases, 2007. 7: p. 27–27. https://doi.org/10.1186/1471-2334-7-27 PMID: 17437632

75. Vallee A., et al., The prevalence of sexually transmitted infections in Papua New Guinea: a systematic review and meta-analysis. PloS one, 2010. 5(12): p. e15586–e15586. https://doi.org/10.1371/journal.pone.0015586 PMID: 21203468

76. Hutubessy R., Chisholm D., and Edejer T.T., Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc, 2003. 1(1): p. 8. https://doi.org/10.1186/1478-7547-1-8 PMID: 14687420

77. Phang Romero Casas C., et al., Rapid diagnostic test for antenatal syphilis screening in low-income and middle-income countries: a systematic review and meta-analysis. BMJ Open, 2018. 8(2): p. e018132. https://doi.org/10.1136/bmjopen-2017-018132 PMID: 29467132

78. Gaydos C. and Hardick J., Point of care diagnostics for sexually transmitted infections: perspectives and advances. Expert review of anti-infective therapy, 2014. 12(6): p. 657–672. https://doi.org/10.1586/14787210.2014.880651 PMID: 24484215

79. Causer L.M., et al., Molecular test for chlamydia and gonorrhoea used at point of care in remote primary healthcare settings: a diagnostic test evaluation. Sexually Transmitted Infections, 2018. 94(5): p. 340–345. https://doi.org/10.1136/sextrans-2017-053443 PMID: 29748180

80. Gadoth A., et al., Prenatal chlamydial, gonococcal, and trichomonal screening in the Democratic Republic of Congo for case detection and management. International Journal of STD & AIDS, 2020. 31 (3): p. 221–229.

81. Byford S. and Raftery J., Perspectives in economic evaluation. 1998. 316(7143) : p. 1529–1530.

82. Bert F., et al., HIV screening in pregnant women: A systematic review of cost-effectiveness studies. Int J Health Plann Manage, 2018. 33(1): p. 31–50. https://doi.org/10.1002/hpm.2418 PMID: 28556453
88. Verguet S., et al., Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis. Vaccine, 2013. 31(42): p. 4902–4910. https://doi.org/10.1016/j.vaccine.2013.07.014 PMID: 23871824

89. Verguet S., et al., Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. The Lancet Global Health, 2015. 3(5): p. e288–e296. https://doi.org/10.1016/S2214-109X(14)70346-8 PMID: 25889470